Last updated on December 2019

Trial to Compare the Safety Efficacy and Immunogenicity of TX05 With Herceptin in HER2+ Early Breast Cancer

Brief description of study

This is a Phase III, double-blind, randomized, multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of TX05 (trastuzumab) with Herceptin in subjects with HER2 positive early breast cancer.

Clinical Study Identifier: NCT03556358

Find a site near you

Start Over

Tanvex Investigational Site 1535

Arkhangel'sk, Russian Federation
  Connect »